Who could enter the quitting study—and who actually did?

Separate allowed entry from actual entry

A methods section can list permitted ages, product-use conditions, location, or access requirements. A participant table then describes those who entered. These documents answer different questions. Everyone meeting the criteria may not have been invited or willing to join, and the actual sample can occupy only part of the permitted range. Do not use an allowed age range as a description of every participant.

NCI explains that eligibility criteria characterize a trial population and that unnecessarily narrow criteria can limit applicability. Its page concerns cancer research; we use only that general population-scope distinction. No cancer criteria, findings, or enrollment advice are transferred to vaping. The particular quitting report must supply its own conditions before any applicability discussion can begin.

US National Cancer Institute: Implementing Criteria to Expand Clinical Trial Eligibility

Build three boxes for one claim

Label an original reading note eligible, reached by recruitment, and enrolled. In the first, copy the stated conditions. In the second, describe the invitation route. In the third, note the reported participant characteristics and uncertainty. A randomized allocation statement belongs after these entry stages; it does not turn the recruitment route into a random sample of all US adults.

Imagine a fictional program trial permitting adult participants but recruiting through one workplace. Many eligible adults outside that workplace may never encounter the invitation. An enrolled table may describe volunteers from that route. The example does not establish an actual trial limitation or workplace result. It shows why broadly permitted entry and broad observed representation are not interchangeable.

Identify the condition relevant to your question

If a claim is directed at you, ask what difference matters to the option you are considering: language, access route, use pattern, or delivery setting, for example. A mismatch does not automatically prove no benefit outside the study. It identifies an uncertainty that the report alone may not settle. Do not select a favorable subgroup number to fill the gap without its own supporting comparison.

This question differs from why a systematic review excludes a whole study. Here the unit is the person who could enter a primary study, not the report meeting a review’s criteria. Keep both layers clear when reading a review: an eligible study can still contain a restricted participant population. An inclusion label at either layer is not a universal clinical suitability certificate.

Ask about applicability without self-screening

A concise evidence question is: this report observed these participants under these access conditions; how does that affect interpretation for the actual support available to me? Bring the report to a qualified professional if a health decision depends on it. Do not change treatment or reinterpret medical criteria yourself to resemble a studied group.

If the issue is an invitation to participate, use the verified research team’s process to ask about eligibility and the study’s purpose. This guide does not recommend joining or promise acceptance. Its reading output is a population description with the distinction between permitted, reached, and enrolled people intact. That is more useful than either claiming the result applies to everyone or dismissing all evidence because no sample includes everyone.